N~2~-Formyl-L-valinamide | 59905-79-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N~2~-Formyl-L-valinamide
• 英文别名: (2S)-2-formamido-3-methylbutanamide
• CAS: 59905-79-2
• 化学式: C₆H₁₂N₂O₂
• 分子量: 144.17
• InChiKey: LLRZMHIKPHOQDN-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  72.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] FUSED RING INHIBITORS OF HEPATITIS C<br/>[FR] INHIBITEURS À NOYAUX FUSIONNÉS DE L'HÉPATITE C
  申请人：PRESIDIO PHARMACEUTICALS INC

  公开号：WO2010111534A1

  公开（公告）日：2010-09-30

  Provided herein are compounds, pharmaceutical compositions and combination therapies for treatment of hepatitis C.

  本文提供了治疗丙型肝炎的化合物、药物组合和联合疗法。
• [EN] PROTEASE INHIBITORS AS ANTIVIRALS<br/>[FR] INHIBITEURS DE PROTÉASE UTILISÉS COMME ANTIVIRAUX
  申请人：ACEA THERAPEUTICS INC

  公开号：WO2022256434A1

  公开（公告）日：2022-12-08

  Provided herein,inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III) and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.

  本文提供了与治疗由冠状病毒或肠道病毒引起的病毒感染相关的化合物、药物组合物和治疗方法。本文提供了公式(I)、(II)和(III)化合物以及使用这些化合物进行治疗的方法。这些化合物是肽类模拟物，能够抑制冠状病毒的蛋白酶3CL，并且可用于治疗由病毒感染引起的疾病，包括COVID-19。
• Amidase from variovorax
  申请人：Degussa AG

  公开号：US20030186423A1

  公开（公告）日：2003-10-02

  The present invention relates to an amidase enzyme, nucleic acids encoding the amidase, as well as methods of employing the nucleic acids and/or amidase to produce, for example, enantiomericallyenriched compounds such as D-amino acids.
• PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF
  申请人：REGENERON PHARMACEUTICALS, INC.

  公开号：US20220072141A1

  公开（公告）日：2022-03-10

  Described herein are protein-drug conjugates and compositions thereof that are useful, for example, for target-specific delivery of therapeutic moieties, e.g., camptothecin analogs and/or derivatives. In certain embodiments, provided are specific and efficient methods for producing protein-drug constructs (e.g., antibody-drug conjugates) utilizing a combination of transglutaminase and 1,3-cycloaddition techniques. Camptothecin analogs, antibody-drug conjugates, and compositions which comprise glutaminyl-modified antibodies and camptothecin analog payloads and are provided.
• US7070963B2
  申请人：——

  公开号：US7070963B2

  公开（公告）日：2006-07-04